Philadelphia – Day 3 of the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting continues to deliver on high quality talks with excellent data to discuss and parse.
Dr Jay Bradner (NIBR) at #Targets17
The session on epigenetics and transcription factors is always one of my favourites and this year didn’t disappoint.
There were also sessions on imaging, non-mutated genes, the tumour microenvironment and of course, a long poster session to browse. Thankfully the poster halls weren’t as mobbed as they were at ASCO earlier in the year, but they were still pretty busy and well attended.
To learn more insights from this cancer conference, subscribers can log-in or you can click to gain access to BSB Premium Content.
Have you ever sat in a freezing cold scientific session and been so engrossed in the compelling presentations that followed, you simply forgot to take notes? Not one. That actually happened to me at the American Association for Cancer Research (AACR) in Philadelphia this year in one of the many fringe sessions that I attended.
Reading Terminal Clock, Philadelphia
Granted, the hot topic of the conference was undoubtedly checkpoint inhibition, but I was anxious to escape to the comfort of some meaty and familiar basic and translational science, namely MYC. MYC is largely thought to be a difficult to target, even undruggable protein, and along with RAS and p53, represents a formidable challenge for cancer researchers. These three oncogenic proteins alone are probably responsible for more drug resistance developing and even death from cancer than any other proteins in a patient with advanced disease.
For cancer patients with advanced disease, the clock is ticking on time they have left.
Solve these three problems (MYC, RAS and p53) and we may have a shot at dramatically improving outcomes. As Dr Gerard Evan (Cambridge) noted:
“I think it’s fair to say that we don’t really know why interruption of any oncogenic signal actually kills cancer cells, but one of the reasons that we’re interested in MYC is because it seems to be a common downstream effector of many, maybe all cancers.”
Sure, the road to success is paved with an enormous graveyard of failures, just as metastatic melanoma was before checkpoint blockade came along, ironically. What I heard at AACR both inspired and filled me with greater confidence… we’re finally getting somewhere.
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.